Abstract
Advances in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer continue to shape clinical practice. At JADPRO Live, presenters discussed the evolving therapeutic landscape, highlighting the role of CDK4/6 inhibitors, biomarker-driven targeted therapies, antibody-drug conjugates, and PARP inhibitors. With a focus on efficacy, patient selection, and the management of adverse events, they discussed the importance of personalized medicine in optimizing treatment outcomes. As resistance mechanisms become better understood, next-generation sequencing and emerging therapies offer new avenues for patients.
